(Q36157284)

12 August 2017

1 reference

title

Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer (English)

1 reference

12 August 2017

1 reference

Brian J Byrne

1

1 reference

PubMed ID

15946581

12 August 2017

Jennifer Garst

series ordinal

2

1 reference

12 August 2017

1 July 2005

1 reference

12 August 2017

Current Oncology Reports

1 reference

12 August 2017

7

1 reference

12 August 2017

4

1 reference

12 August 2017

241-247

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-005-0045-6

12 August 2017

0 references

cites work

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

ErbB-targeted therapeutic approaches in human cancer

1 reference

12 December 2020

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

1 reference

12 December 2020

Cancer statistics, 2005

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

Interstitial lung disease associated with drug therapy

1 reference

12 December 2020

Targeting the epidermal growth factor receptor

1 reference

12 December 2020

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

1 reference

12 December 2020

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

1 reference

12 December 2020

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

1 reference

12 December 2020

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

HER1/EGFR targeting: refining the strategy

1 reference

12 December 2020

10.1007/S11912-005-0045-6

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15946581